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Background: Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a
substantially increased breast cancer risk. Little is known about how menarcheal and reproductive factors modify this risk.
Methods: We examined the effects of menarcheal age, pregnancy, and menopausal age on breast cancer risk following sRT in case–
control data from questionnaires completed by 2497 women from a cohort of 5002 treated with sRT for HL at ageso36 during 1956–2003.
Results: Two-hundred and sixty women had been diagnosed with breast cancer. Breast cancer risk was significantly increased in
patients treated within 6 months of menarche (odds ratio (OR) 5.52, 95% confidence interval (CI) (1.97–15.46)), and increased
significantly with proximity of sRT to menarche (Ptrendo0.001). It was greatest when sRT was close to a late menarche, but based
on small numbers and needing reexamination elsewhere. Risk was not significantly affected by full-term pregnancies before or
after treatment. Risk was significantly reduced by early menopause (OR 0.55, 95% CI (0.35–0.85)), and increased with number of
premenopausal years after treatment (Ptrend¼ 0.003).
Conclusion: In summary, this paper shows for the first time that sRT close to menarche substantially increases breast cancer risk.
Careful consideration should be given to follow-up of these women, and to measures that might reduce their future breast cancer risk.
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Survival rates in Hodgkin lymphoma (HL) patients have improved
greatly over the past few decades (Diehl et al, 2004), due to
improvements in treatment techniques. As a consequence, late
effects of HL treatment are becoming an increasing problem, with
survivors experiencing increased risks of second malignancies (van
Leeuwen et al, 2007). A major concern is the greatly increased
breast cancer risk in young women treated for HL with
supradiaphragmatic radiotherapy (sRT), who face cumulative risks
of up to 48% of developing breast cancer by 40 years after
treatment (Swerdlow et al, 2012). It is important to understand
how breast cancer risk in these patients is modified by other
factors. Treatment age, field of sRT, and treatment with alkylating
chemotherapy (CT) or pelvic radiotherapy (RT) have been
identified as factors that affect this risk (van Leeuwen et al, 2007;
Inskip et al, 2009; Swerdlow et al, 2012). Menarche, pregnancy, and
menopause are periods in life that have been considered critical to
breast cancer risk (Hankinson et al, 2004; Colditz et al, 2006), and
although a reduced risk of breast cancer has been identified in
women who experience early menopause following HL treatment
(Travis et al, 2003; van Leeuwen et al, 2003), little research has
been carried out into how menarcheal and reproductive factors
affect breast cancer risk after sRT. The high risks for women
irradiated at young ages (Hancock et al, 1993; Bhatia et al, 1996;
Mauch et al, 1996; Sankila et al, 1996; Aisenberg et al, 1997;
Metayer et al, 2000; De Bruin et al, 2009; Swerdlow et al, 2012)
imply that puberty might be a time of raised susceptibility. The
rapid differentiation that occurs in the breast during a first
pregnancy (Russo et al, 1992) suggests the possibility of a raised
breast cancer risk following exposure during first pregnancy, at
least. We have, therefore, investigated the effect of menarcheal age,
pregnancy, and menopausal age in 2497 women treated with sRT
for HL at ages p35 years.
PATIENTS AND METHODS
Data collection. A cohort of 5002 women treated with sRT for HL
at ages p35 years during 1956–2003 in England and Wales was
identified, and details of their treatment (both initial and at
relapses) and all subsequent breast cancer diagnoses (including
ductal carcinoma in situ) were collected. Follow-up was complete
to the end of 2008 for 97% of patients. Multiple sources were used
to ensure completeness of identification of breast cancers. The
methods are described in detail elsewhere (Swerdlow et al, 2012).
Where possible details of oestrogen receptor (ER) status were
collected from clinical and registry sources. During 2003–2010
cohort members who were alive and resident in the UK were
invited to complete a questionnaire, given to them by consultants
when they attended clinic or sent to them by post. The
questionnaire asked about lifestyle factors, medical history, and
reproductive history, including age at menarche, delivery date and
outcome of pregnancies, disturbances to the menstrual cycle
including changes in frequency and temporary or permanent
cessation, and use of oral contraceptives (OCs) and hormone
replacement therapy (HRT). Blood samples were collected on a
nested case–control basis from women who responded to the
questionnaire, and genotyped for several single-nucleotide poly-
morphisms that have previously been identified as influencing
breast cancer risk, as described elsewhere (Ma et al, 2012).
Medical research ethics approval was granted by the South East
Multi-centre Research Ethics Committee, and patients gave signed
informed consent at the time of questionnaire completion.
Statistical analysis. To investigate the effect of reproductive and
menstrual factors on breast cancer risk, we analysed the data from
questionnaire respondents as a case–control study, with cases being
cohort members diagnosed with breast cancer, and controls being
the cohort members without a known breast cancer diagnosis or
prophylactic bilateral mastectomy.
Not all patients could be included in analyses of the effect of
pregnancy, as some were still at childbearing age when they
completed the questionnaire and hence could have experienced
pregnancies after that date. Cases who completed their question-
naire before the age of 53 and were subsequently diagnosed with
breast cancer were excluded from analyses involving post treatment
pregnancies, as they may have experienced pregnancies between the
questionnaire and the cancer occurrence that were unknown to us.
All patients who completed the questionnaire at ages X53 were
included in these analyses, as it was considered that they were very
unlikely to have experienced further pregnancies. Patients who
completed the questionnaire before age 53 and were either not
diagnosed with breast cancer or diagnosed before completing the
questionnaire were stratum-matched on age and date of first HL
treatment, so that a date comparable to a breast cancer diagnosis
date could be allocated to controls, referred to as the reference date.
This was used to ensure that cases and controls were analysed at a
comparable point in their reproductive history. For cases, the
reference date was defined as the breast cancer diagnosis date. For
controls, the patients were stratified by age and date at start of HL
treatment in 5-year groups and the reference date was calculated by
adding the median time between start of HL treatment and breast
cancer diagnosis in cases in the control’s stratum to the date that
the control began treatment for HL, provided that the reference
date was not later than their questionnaire completion date. For
these patients, pregnancies after the reference date were omitted
from analysis, and controls who could not be allocated a reference
date were excluded from these analyses. The same reference date
and exclusions were applied to the analysis of number of
premenopausal years after the start of treatment.
Details of any disturbances in a patient’s menstrual cycle were
used to define whether she had experienced premature menopause,
at ageso40, or had reached menopauseo5 years from start of HL
treatment. Patients who had not yet reached age 40 or had been
diagnosed with breast cancer before age 40 were excluded from
analyses of premature menopause, and those who had completed
the questionnaire within 5 years of starting treatment or had been
diagnosed with breast cancer within 5 years of starting treatment
were excluded from analyses of menopause within 5 years of
treatment. Patients who had undergone oophorectomy or
hysterectomy (as this often includes oophorectomy) were con-
sidered to be postmenopausal from the date of surgery.
Menopausal status at each time point was considered unknown
if the patient was using OCs or a contraceptive implant, injection
or hormonal (Mirena) coil, or HRT, and had not reported going
through menopause before then, and was considered unknown
at all time points if the patient completed the questionnaire at
age X53 and did not mention having gone through menopause.
Seven patients who stated that they had never experienced a
natural menarche due to HL treatment at an early age were
considered postmenopausal from 6 months after their final HL
treatment. The stratum matching carried out for pregnancy
analyses was also used in the analysis of premenopausal years
following HL treatment.
Breast cancer risks were estimated using unconditional logistic
regression to calculate odds ratios (OR), 95% confidence intervals
(CI) and two-sided P-values (Breslow and Day, 1980). Models were
adjusted for all, or where appropriate a subset, of: age and calendar
year at first HL treatment, interval between start of HL treatment
and questionnaire completion, calendar year of birth, whether the
patient received ovarian-toxic treatment (X5Gy pelvic RT or any
cycles of alkylating CT), and field of sRT (mantle, other, or
unknown). Trend tests were carried out on ordinal variables using
a likelihood ratio test. Analyses were conducted using Stata
(StataCorp, 2007), with no imputation for missing values.
BRITISH JOURNAL OF CANCER Breast cancer after RT for Hodgkin lymphoma
2400 www.bjcancer.com |DOI:10.1038/bjc.2013.219
RESULTS
We received questionnaires from 2508 women from the cohort of
5002. Of the remainder, 1105 had died, 999 were mailed but did
not complete a questionnaire, 35 had emigrated, and 355
were not known to have died or emigrated but were not contacted
for other reasons. Of those who returned a questionnaire, 149 had
had breast cancer diagnosed before completing it, 111 have had
breast cancer diagnosed since completing it, and 2248 are not
known to have had breast cancer. Eleven patients indicated that
they had had prophylactic bilateral mastectomies, and were,
therefore, excluded from analyses. Patients who were alive
but did not complete a questionnaire did not differ significantly
from those who did in terms of calendar year or age of treatment,
or type of treatment received (not in tables). Those who had died
were treated at similar ages to those who took part, but
significantly more were treated in early years, and a significantly
higher proportion received ovarian-toxic treatments (not in tables).
There was a significantly higher proportion of breast cancer
cases in the group of patients who participated than in the group
who were alive but did not participate, or those who had died
(not in tables).
The median age at first HL treatment among patients who
completed a questionnaire was 24.3 years, and 25% were treated
before age 20 (Table 1). Thirty-two percent of patients were treated
with sRT alone, 61% with sRT in combination with ovarian-toxic
treatment, and 7% received sRT but it was unknown whether they
received other treatments. Questionnaires were completed a
median of 17.2 years after first treatment.
The mean age at menarche was 13.5 years (Table 2). At
menarcheal ages o15, there was no apparent effect of age at
menarche on breast cancer risk; however, risks were progressively
and greatly raised in patients with the oldest menarcheal ages,
significantly so for ages 16 (OR 2.65, 95% CI (1.28–5.48)) and
17 (OR 3.74, 95% CI (1.08–12.98)) compared with age 13 (Table 2).
The menarcheal age results were not materially altered by:
adjustment for rapidity of onset of menopause after treatment;
separately analysing patients treated with sRT only (n¼ 785) and
those who also received ovarian-toxic treatments (n¼ 1565)
(although higher ORs were found with older menarcheal ages in
the ovarian-toxic treatment group); analysing risk of ER positive
(n¼ 100) and negative (n¼ 33) breast cancer separately (although
a higher OR was found with the oldest menarcheal ages for
ER-positive cancer); analysing risk of invasive breast cancer only
(n¼ 182); repeating the analysis adding the seven patients who did
not experience a natural menarche (using their age of induced
menarche as a substitute for natural menarcheal age); restricting
analysis to patients who received 35–40Gy mantle RT only
(n¼ 984); or restricting analysis to those treated X10 years after
menarche (n¼ 1370) (not in tables). Analysis of FGFR2 genotype,
which was significantly associated with breast cancer risk in these
women (Ma et al, 2012) (n¼ 436), found no association between
genotype and menarcheal age (not in tables).
The proximity of sRT to menarche had a strong effect on risk:
patients who received sRT within 5 years of menarche experienced
a significantly raised breast cancer risk compared with those
treated X10 years after menarche, with a peak 5.5-fold risk (95%
CI (1.97–15.46)) in those treated within 6 months of menarche
(Table 2). There was a significant trend of decreasing breast cancer
risk with increasing time between menarche and sRT
(Ptrendo0.001). Although the effect of treatment close to menarche
was present for both those with early or normal menarche (aged
o15 years) and those with late menarche (agedX15 years), it was
greater in the latter group; breast cancer risk reached a 15.6-fold
increase (95% CI (3.92–62.22)) in those treated 0.5–2 years after a
late menarche compared with those treated X10 years after a
normal-age menarche, which was highly significant, although
based on small numbers.
Patients who had experienced a full-term pregnancy (FTP) had
a similar breast cancer risk to those who had not experienced any
FTPs (OR 1.17, 95% CI (0.79–1.73)) (Table 3). Patients who had
experienced a FTP before receiving sRT had a non-significantly
Table 1. Descriptive characteristics of breast cancer cases and controls
Characteristic
Cases
(n¼260)
No. (%)
Controls
(n¼2237)
No. (%) Total
Age at first treatment for HL, years
0–9 2 (0.8) 20 (0.9) 22
10–14 24 (9.2) 71 (3.2) 95
15–19 85 (32.7) 424 (19.0 ) 509
20–24 75 (28.9) 669 (29.9) 744
25–29 39 (15.0) 574 (25.7) 613
30–35 35 (13.5) 479 (21.4) 514
Calendar year of first treatment for HL
1960–1969 20 (7.7) 65 (2.9) 85
1970–1979 110 (42.3) 361 (16.1) 471
1980–1989 99 (38.1) 684 (30.6) 783
1990–1999 30 (11.5) 912 (40.8) 942
2000–2004 1 (0.4) 215 (9.6) 216
HL treatment
sRT only 113 (43.5) 688 (30.8) 801
sRT and X 5Gy pelvic RT 0 (0.0) 19 (0.9) 19
sRT and alkylating CT 116 (44.6) 1345 (60.1) 1461
sRT, X 5Gy pelvic RT and
alkylating CT
7 (2.7) 42 (1.9) 49
sRT, unknown if pelvic RT or
alkylating CT
24 (9.2) 143 (6.4) 167
Calendar year of questionnaire completion
2003–2005 83 (31.9) 911 (40.7) 994
2006–2008 161 (61.9) 1188 (53.1) 1349
2009–2011 16 (6.2) 138 (6.2) 154
Interval between first treatment for HL and questionnaire
completion, years
0–9 4 (1.5) 566 (25.3) 570
10–19 56 (21.5) 860 (38.4) 916
20–29 116 (44.9) 548 (24.5) 664
30 or over 84 (32.0) 263 (11.8) 347
Age at breast cancer diagnosis, years
Less than 30 7 (2.7) — 7
30–39 57 (21.9) — 57
40–49 128 (49.2) — 128
50–59 52 (20.0) — 52
60–69 16 (6.2) — 16
Interval between first treatment for HL and breast cancer
diagnosis, years
0–9 3 (1.2) — 3
10–19 84 (32.3) — 84
20–29 127 (48.8) — 127
30–39 42 (16.2) — 42
40 or over 4 (1.5) — 4
Abbreviations: CT¼ chemotherapy; HL¼Hodgkin lymphoma; RT¼ radiotherapy;
sRT¼ supradiaphragmatic radiotherapy.
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reduced breast cancer risk compared with those who had not (OR
0.77, 95% CI (0.52–1.12)), with similar results when patients
treated with and without ovarian-toxic treatments were analysed
separately (not in tables), and patients who had experienced a FTP
after sRT had a non-significantly raised risk (OR 1.33, 95% CI
(0.92–1.92)). There was no evidence that proximity of sRT to first
FTP affected breast cancer risk (Table 3). Ninety-two cases were
excluded from pregnancy analyses because they completed their
questionnaire before the age of 53 and were subsequently
diagnosed with breast cancer, and 1056 controls were excluded
because they could not be allocated a reference date; results were
similar if a cutoff age of 45 was used instead of 53 (not in tables).
Thirty-six percent of those who completed the questionnaire at
ages X40 had experienced premature menopause. These patients
Table 2. Risks of breast cancer after supradiaphragmatic radiotherapy in relation to age at menarche
Risk factor Cases Controls Total ORa (95% CI) P-value
Age at menarche, years
8–10 11 92 103 1.32 (0.64–2.72) 0.44
11 40 359 399 1.05 (0.67–1.65) 0.84
12 53 453 506 1.25 (0.82–1.91) 0.29
13 55 564 619 1.00
14 39 378 417 0.94 (0.60–1.48) 0.79
15 29 209 238 1.45 (0.87–2.41) 0.16
16 13 61 74 2.65 (1.28–5.48) 0.009
17 5 15 20 3.74 (1.08–12.98) 0.04
18–19 2 6 8 3.89 (0.54–28.16) 0.18
Never 1 6 7 0.94 (0.09–9.98) 0.96
Unknown 12 94 106 1.23 (0.61–2.47) 0.56
Ptrend¼0.10
Duration between menarche and sRT
sRT at least 5 years before menarche 1 10 11 0.94 (0.10–8.46) 0.95
sRT 2–5 years before menarche 6 16 22 4.08 (1.27–13.14) 0.02
sRT 0.5–2 years before menarche 7 12 19 4.90 (1.60–14.98) 0.005
sRT within 6 months of menarche 9 14 23 5.52 (1.97–15.46) 0.001
sRT 0.5–2 years after menarche 9 29 38 3.47 (1.40–8.58) 0.007
sRT 2–5 years after menarche 45 200 245 2.38 (1.43–3.97) 0.001
sRT 5–10 years after menarche 67 577 644 1.33 (0.89–1.98) 0.16
sRT at least 10 years after menarche 99 1271 1370 1.00
Never 1 6 7 2.14 (0.20–22.56) 0.53
Unknown 16 102 118 1.67 (0.90–3.11) 0.11
Ptrend
bo0.001
Duration between menarche and sRT by age at menarche
Patients with menarche at 14 years or earlier
sRT at least 5 years before menarche 0 6 6 — —
sRT 2–5 years before menarche 3 11 14 2.91 (0.64–13.24) 0.17
sRT 0.5–2 years before menarche 2 8 10 2.01 (0.38–10.76) 0.41
sRT within 6 months of menarche 6 10 16 5.64 (1.63–19.53) 0.006
sRT 0.5–2 years after menarche 3 24 27 1.27 (0.34–4.79) 0.72
sRT 2–5 years after menarche 37 156 193 2.49 (1.44–4.32) 0.001
sRT 5–10 years after menarche 55 487 542 1.24 (0.81–1.91) 0.32
sRT at least 10 years after menarche 89 1136 1225 1.00
Patients with menarche at 15 years or later
sRT at least 5 years before menarche 1 4 5 2.77 (0.26–29.78) 0.40
sRT 2–5 years before menarche 3 5 8 6.12 (1.14–32.86) 0.04
sRT 0.5–2 years before menarche 5 4 9 11.34 (2.41–53.40) 0.002
sRT within 6 months of menarche 3 4 7 4.94 (0.97–25.12) 0.05
sRT 0.5–2 years after menarche 6 5 11 15.61 (3.92–62.22) o0.001
sRT 2–5 years after menarche 8 44 52 1.84 (0.77–4.41) 0.17
sRT 5–10 years after menarche 12 90 102 1.87 (0.93–3.75) 0.08
sRT at least 10 years after menarche 10 135 145 1.14 (0.56–2.30) 0.72
Unknown 17 108 125 1.69 (0.92–3.12) 0.09
Abbreviations: CI¼ confidence interval; OR¼odds ratio; sRT¼ supradiaphragmatic radiotherapy.
aOdds ratios are adjusted for year of treatment, duration between treatment and questionnaire completion, calendar year of birth, sRT field, ovarian-toxic treatment; age at menarche also
adjusted for age at treatment.
bAbsolute interval between menarche and sRT.
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had a significantly reduced breast cancer risk (OR 0.65, 95% CI
(0.44–0.94)) compared with those still premenopausal at age 40
(Table 4). Similar results were found when this analysis was
repeated for menopausal status at age 35 (OR 0.69, 95% CI (0. 47–
1.02)) or age 45 (OR 0.54, 95% CI (0.35–0.84)) (not in tables).
Within the 2358 patients who completed the questionnaire X5
years after HL treatment, there was a significantly reduced breast
cancer risk in those who reached menopause within 5 years of
starting treatment (OR 0.55, 95% CI (0.35–0.85)) (Table 4). Breast
cancer risk increased significantly with increasing number of
premenopausal years following treatment (Ptrend¼ 0.003).
Analyses were repeated adjusting for use of OCs or HRT, with
no material difference to results.
DISCUSSION
Women treated with sRT for HL at young ages are known to be at
greatly increased risk of breast cancer; consequently it is important
to understand how this raised risk is modified by other factors.
Analyses of the effect of age at sRT find greatest risks for treatment
in the early teenage years (Bhatia et al, 1996; Metayer et al, 2000;
Inskip et al, 2009; Swerdlow et al, 2012), or in the first two decades
of life (Hancock et al, 1993; Mauch et al, 1996; Aisenberg et al,
1997; De Bruin et al, 2009); similarly, analysis of breast cancer risk
in atomic bomb survivors has found a significantly decreasing risk
with increasing age at exposure (Land et al, 2003). No studies,
however, have examined directly whether sRT close to menarche,
when the breast is developing, is particularly hazardous. We were
able to categorise patients according to time between menarche
and sRT, and found a clear trend for greater breast cancer risks the
closer that exposure was to menarche; this applied both to patients
treated before menarche and those treated after menarche.
On average, pubertal breast development begins 2.3 years before
menarche, continuing for 2.1 years afterwards (Marshall and
Tanner, 1969); this period corresponds to the categories where we
found the highest and most significantly raised breast cancer risks.
Our result is, therefore, consistent with the theory that suscept-
ibility of the breast to carcinogens is particularly high around
menarche (Korenman, 1980; Russo and Russo, 1997).
It has been consistently shown that older menarcheal age
confers a protective effect against breast cancer in the general
population (Colditz et al, 2006). Thus, the increased breast cancer
risk we found in sRT patients with a late menarche seems at first
sight surprising. Risk in relation to older menarcheal age in HL
patients has been investigated in one, much smaller, previous study
(van Leeuwen et al, 2003), which found a somewhat raised risk
with menarche at ages X15 years, but with a wide CI based on
only eight cases with menarche at these ages. The raised risk that
we found with late menarche remained when we adjusted for
menopausal age, added patients who never experienced natural
menarche following HL treatment at young ages, analysed
separately patients treated with sRT only and those also treated
with ovarian-toxic treatments, analysed separately by ER status,
and restricted to invasive cancers only. Our results thus suggest
that the relationship between menarcheal age and breast cancer
risk might be different in heavily irradiated women from that in
the general population, although as they are based on small
Table 3. Risks of breast cancer after supradiaphragmatic radiotherapy in
relation to pregnancy history
Risk factor Cases Controls Total ORa (95% CI) P-value
Any full-term pregnancies
No 46 365 411 1.00
Yes 122 814 936 1.17 (0.79–1.73) 0.42
Unknown 0 2 2 — —
Full-term pregnancy before start of sRT
No 203 1516 1719 1.00
Yes 57 717 774 0.77 (0.52–1.12) 0.17
Unknown 0 4 4 — —
Full-term pregnancy after start of sRT
No 74 637 711 1.00
Yes 94 542 636 1.33 (0.92–1.92) 0.13
Unknown 0 2 2 — —
Timing of first FTP in relation to sRT
No FTPs 42 351 393 1.00
1st FTP more than
10 years before sRT
9 54 63 1.52 (0.59–3.88) 0.38
1st FTP 5–10 years
before sRT
8 110 118 0.64 (0.27–1.55) 0.32
1st FTP o5 years
before sRT
23 206 229 1.03 (0.57–1.84) 0.93
sRT during 1st FTP 2 10 12 1.81 (0.35–9.33) 0.48
1st FTP o5 years
after sRT
33 198 231 1.41 (0.83–2.38) 0.20
1st FTP 5–10 years
after sRT
27 142 169 1.39 (0.79–2.44) 0.26
1st FTP 410 years
after sRT
17 70 87 1.25 (0.63–2.49) 0.52
Unknown 7 40 47 1.03 (0.40–2.63) 0.95
Abbreviations: CI¼ confidence interval; FTP¼ full-term pregnancy; OR¼odds ratio;
sRT¼ supradiaphragmatic radiotherapy.
aOdds ratios are adjusted for age and year of treatment, duration between treatment and
questionnaire completion, calendar year of birth, sRT field, ovarian-toxic treatment.
Table 4. Risks of breast cancer after supradiaphragmatic radiotherapy in
relation to age at menopause
Risk
factor
Cases Controls Total ORa (95% CI) P-value
Menopause before age 40
No 103 598 701 1.00
Yes 49 454 503 0.65 (0.44–0.94) 0.02
Unknown 32 168 200 1.09 (0.69–1.73) 0.70
Menopause within 5 years of start of treatment
No 205 1399 1604 1.00
Yes 26 357 383 0.55 (0.35–0.85) 0.01
Unknown 34 337 371 0.92 (0.61–1.38) 0.68
Premenopausal years after start of treatment
Less than 1 10 103 113 1.00
1–4 7 98 105 0.96 (0.34–2.69) 0.94
5–9 7 84 91 1.02 (0.36–2.87) 0.97
10–14 19 277 296 1.49 (0.63–3.55) 0.36
15–24 49 281 330 1.62 (0.76–3.44) 0.21
25 or over 25 40 65 3.56 (1.50–8.45) 0.004
Unknown 52 294 346 1.74 (0.84–3.64) 0.14
Ptrend¼ 0.003
Abbreviations: CI¼ confidence interval; OR¼odds ratio; sRT¼ supradiaphragmatic radio-
therapy.
aOdds ratios are adjusted for age and year of treatment, duration between treatment and
questionnaire completion, calendar year of birth, sRT field.
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numbers it would be desirable to repeat these analyses in other
similar cohorts.
Analysis of the proximity of sRT to menarche found that the
raised risk in patients irradiated close to menarche was particularly
high in those with late menarche, although risk for those with late
menarche remained somewhat raised even if they received sRT
X10 years later. Menarche can be delayed because of poor health
(Neinstein, 1985), which suggests the possibility that late menarche
could have been a marker of more unwell patients who received
greater radiation doses. This potential confounding did not explain
the results, however, as the effect remained when we restricted the
analysis to patients who received 35–40Gy mantle RT.
It has been shown that around half of the variation in timing of
menarche in the general population is attributable to genetic factors
(Morris et al, 2011), and several genes associated with menarcheal
age have been identified (Dvornyk and Ul-Haq, 2012). It is thought
that there is also an element of genetic predisposition involved in
radiosensitivity (Burrill et al, 2000; Gatti, 2001), and hence a
potential explanation for our finding could be genetic linkage
between loci associated with these two factors. A previous study
including a subset of our patients found that FGFR2 was associated
with radiation-induced breast cancer risk (Ma et al, 2012); however,
analysing the same subset we found no evidence of an association
between FGFR2 genotype and menarcheal age.
In the general population, later menarche is associated with
greater height (Onland-Moret et al, 2005) and lower body mass
index (BMI) in adulthood (Pierce and Leon, 2005); this was also
true in our study. Height has a small positive association with
breast cancer risk (Gunnell et al, 2001) and low BMI is associated
with an increased risk of premenopausal breast cancer (van den
Brandt et al, 2000). It is implausible, however, that these
associations could account for the risks that we found with late
menarche, as the effects are small compared with the difference in
effect of menarcheal age in the irradiated women from that in the
general population.
High breast density is one of the strongest known breast cancer
risk factors (McCormack and dos Santos Silva, 2006). Some studies
have found evidence of a positive association between breast
density and menarcheal age (Sala et al, 2000; Titus-Ernstoff et al,
2006; Butler et al, 2008), although others have found no association
(Vachon et al, 2000; Maskarinec et al, 2006). The raised risk that
we found with late menarche could not directly be a consequence
of the association between breast density and breast cancer risk,
however, as this would also hold in the general population, in
whom late menarche is not associated with raised breast cancer
risk. Also, the size of the putative association of menarcheal age
and breast density is too small.
Evidence from some small studies (Marti-Henneberg and
Vizmanos, 1997; Pantsiotou et al, 2008) suggests an association
between early onset of puberty and greater duration of breast
growth, although others found no association (Marshall and
Tanner, 1969; Largo and Prader, 1983). This suggests the
possibility that the increased breast cancer risk we found in
patients treated close to a late menarche might be due to more
rapid pubertal breast growth in these patients, with the increased
rate of cell division at this time resulting in greater susceptibility of
the breast to carcinogenesis. We are unable to investigate this
further, however, as data on breast development in the study
subjects were not collected.
The breast undergoes rapid change during first FTP (Russo et al,
1992), and it has been suggested that this may result in increased
breast cancer risk in patients treated with sRT during first FTP
(Ronckers et al, 2005). Only one previous study has examined
breast cancer risk after irradiation during pregnancy in HL
patients; this found a significantly increased risk, although based
on very small numbers and with limited follow-up (Chen et al,
2004). We found no significant effect of irradiation during first
FTP on breast cancer risk, based on 12 cases irradiated. There was
also no significant difference in risk between women who had ever
had a FTP and those who had not, contrary to the position in the
general population in whom completion of a FTP confers a long-
term protective effect against breast cancer (Colditz et al, 2006).
Risk was slightly reduced in patients who had had a FTP before
sRT however, consistent with the theory that susceptibility of the
breast to carcinogens is reduced after first FTP (Russo and Russo,
1995), and the slight increase in risk in patients who had had a FTP
after sRT, likely caused by confounding by the effect of continued
ovarian function after HL treatment, may explain the lack of
reduced risk following FTP overall. Our results are consistent with
those from two previous smaller studies, based on 51 and 37
parous cases, respectively (van Leeuwen et al, 2003; Hill et al,
2005), which also found no significant effect of pregnancies before
or after HL on breast cancer risk.
Early menopause is known to have a protective effect on breast
cancer risk in the general population (Trichopoulos et al, 1972; La
Vecchia et al, 1992), and HL patients frequently experience early
menopause as a consequence of ovarian-toxic treatment (De Bruin
et al, 2008). Previous studies have found significantly reduced
breast cancer risks in HL patients who experience premature
menopause compared with those who maintain ovarian function
post treatment (Travis et al, 2003; van Leeuwen et al, 2003), with
risk increasing with number of premenopausal years after
treatment (van Leeuwen et al, 2003). Our results add to the
evidence, based on larger numbers: we found significant reductions
in risk in both those who experienced menopause at ageso40, and
those who experienced menopause o5 years after starting
treatment, and a significantly increasing breast cancer risk with
increasing number of premenopausal years post treatment.
As we only received questionnaires from half of the original
cohort members, there is the possibility that those who responded
could have been biased in some way. It seems implausible,
however, that patients would have replied or not depending on
combinations of their breast cancer status and their age at
menarcheal/reproductive status. Similarly, it seems implausible
that not including patients who had died could have introduced
bias, as this would only occur if mortality were associated with the
combination of breast cancer status and the reproductive factor
being analysed. As our data on menarcheal ages were ascertained
retrospectively, they could be subject to recall bias. Recall of
menarcheal age is generally good, however, even after several
decades (Bean et al, 1979; Must et al, 2002), and there seems no
reason why any misclassification should have been biased, as there
is no association well known to the public that would lead a patient
to misreport their menarcheal age in a certain way depending on
their breast cancer status.
The treatment dates of patients in our cohort cover a
considerable period of time, during which many improvements
to RT techniques were made. To investigate whether effects on
breast cancer risk varied over time we re-ran the analyses
separately by time period; however, because few breast cancers
have occurred to date in the patients treated most recently, it is not
possible to determine any differences at present. As many different
field and dose combinations have been utilised over time we also
re-ran analyses restricted to patients treated with 35–40Gy mantle
RT only, as the largest homogeneous group: results did not
markedly differ from those for the whole cohort. Additionally,
modern RT techniques differ in some respects from those used
when the majority of patients in our study were treated. However,
it is in principle impossible to assess long-term effects of current
techniques until many years in the future, when sufficient time has
elapsed since their introduction. Therefore, the predicted effects of
modern treatment techniques must inevitably for the present be
inferred from analyses of older treatments, as in our and other data
(Aisenberg et al, 1997; Travis et al, 2003; van Leeuwen et al, 2003).
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In conclusion, we have found that risk of breast cancer after sRT
increases when sRT is given closer to menarche, and we have
provided more precise data than previously available, based on
larger numbers, on the effect of menopausal age on RT-related
breast cancer risk. It has previously been hypothesised that the
period around menarche may be a time of greater susceptibility of
the breast to carcinogens (Korenman, 1980; Russo and Russo,
1997), but as far as we know there have been no previous data
showing this directly in humans. Although the result was highly
significant, it would be desirable to reexamine it in other cohorts.
Meanwhile, these high risks should be considered when planning
treatment and screening regimens for HL patients diagnosed close
to menarche. Our results also suggest that research consideration is
needed of the potential value of hormonal suppression of puberty,
as used for instance for precocious puberty (Carel and Le´ger,
2008), in these patients.
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